Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
April 2018
-
Media Release
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial… -
Featured News
Celebrating Community Partnership Day
Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.
-
African experts call for renewed global drive to beat malaria
Survey results highlight the need for concerted action to guard against a fresh upsurge in the disease.
-
Two decades of volunteering at Novartis
The culture of volunteerism is a fundamental part of the Novartis corporate ethos. Here’s a snapshot of our efforts over the years.
-
Media Release
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis… -
Media Release
AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
Includes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a… -
Key Release
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and… -
Media Release
Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments
Hausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto, qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le… -
Media Release
Novartis verzeichnet ein starkes erstes Quartal und ergreift Schritte, um ein stärker fokussiertes Arzneimittelunternehmen zu werden
Der Nettoumsatz steigt um 4% (kWk[1], +10% USD), vor allem dank folgender Beiträge: Entresto wächst um 126% (kWk) auf USD 200 Millionen, da es weltweit vermehrt eingesetzt wird Cosentyx legt um… -
Media Release
Novartis delivered a strong first quarter and acted to become a more focused medicines company
Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong… -
Featured News
Novartis Financial Results – Q1 2018
Today, Novartis CEO Vas Narasimhan announced the company’s financial results for the first quarter of 2018. -
Media Release
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
Pagination
- ‹ Previous page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- …
- 154
- › Next page
Test disclaimer...!!!